Revenue Breakdown
Composition ()
No data
Revenue Streams
United Therapeutics Corp (UTHR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Tyvaso DPI, accounting for 42.1% of total sales, equivalent to $336.20M. Other significant revenue streams include Nebulized Tyvaso and Orenitram. Understanding this composition is critical for investors evaluating how UTHR navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, United Therapeutics Corp maintains a gross margin of 87.38%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 48.69%, while the net margin is 42.36%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively UTHR converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, UTHR competes directly with industry leaders such as MRNA and ZLAB. With a market capitalization of $20.08B, it holds a leading position in the sector. When comparing efficiency, UTHR's gross margin of 87.38% stands against MRNA's 86.22% and ZLAB's 60.13%. Such benchmarking helps identify whether United Therapeutics Corp is trading at a premium or discount relative to its financial performance.
